Most manufactured peptides show negligible toxicity, but some naturally occurring peptides can cause gut damage, immune reactions, and cell toxicity — making safety testing essential before use in food or medicine.
6 toxicity typesIntestinal wall disruption, blood cell toxicity, free radical production, enzyme damage, immune damage, and cytotoxicity are the six main safety concerns with bioactive peptides
What the researchers found
While most manufactured bioactive peptides show negligible toxicity, some naturally occurring peptides and enzymes can induce significant toxicity. The review identifies six main safety concerns with biologically active peptides: intestinal wall disruption, erythrocyte and lymphocyte toxicity, free radical production, enzyme-mediated tissue damage, immune-mediated tissue damage, and direct cytotoxicity.
The authors advocate for systematic safety evaluation — particularly using in silico (computational) methods — before peptides are used in food production or pharmaceutical applications. They emphasize that both immunogenicity (immune reactions against the peptide itself) and direct toxicity need assessment, as the growing use of peptides across food, cosmetics, and medicine demands standardized safety protocols.
Why it matters
As peptides move from research labs into foods, cosmetics, and drugs, the assumption that 'natural means safe' can be dangerous. This review serves as a needed reality check — bioactive peptides have real biological effects, and those effects can include harm if not properly evaluated. With the peptide supplement market booming and minimal regulatory oversight in some sectors, understanding potential toxicity mechanisms is critical for consumer safety.
The numbers in context
6 toxicity mechanisms identified · in silico safety screening recommended · food + cosmetics + pharmaceutical applications reviewed
How the study worked
Systematic literature review searching PubMed, Google Scholar, Medline, EMBASE, Reaxys, and Scopus databases for research and review articles on toxicity of biologically active peptides.
Who was studied
Not applicable — review of peptide toxicity research across food, cosmetic, and pharmaceutical applications
What this study cannot tell us
The review is broad but not deep — covering many types of peptide toxicity without detailed quantitative analysis of any specific category. Much of the toxicity data comes from isolated cell studies rather than whole-organism or clinical observations. The in silico safety prediction tools recommended are still developing and may not capture all toxicity mechanisms.
How to read the evidence
This is a literature review covering peptide toxicity research across multiple databases. While it provides a useful safety framework, the evidence is largely derived from in vitro and animal studies rather than systematic clinical safety data.
When this study was published
Published in 2018 in Current Drug Discovery Technologies. The safety concerns raised remain relevant, though in silico prediction tools have advanced significantly since publication. The growing peptide market makes this topic more pressing than ever.
The bigger picture
The peptide therapeutics and functional foods markets are growing rapidly, but safety frameworks haven't kept pace. While pharmaceutical peptide drugs undergo rigorous FDA review, food-derived peptides and cosmetic peptides often face minimal regulatory scrutiny. This review highlights why that gap matters — biologically active molecules have biological risks, and computational toxicity prediction could provide a scalable first line of safety assessment.
Questions still open
- How reliable are current in silico tools for predicting peptide toxicity before human exposure?
- Which specific bioactive peptides in the food and cosmetics supply have the most concerning safety profiles?
- Should regulatory frameworks require toxicity screening for bioactive peptide-containing functional foods and supplements?
Common questions
Are peptide supplements safe?
What are the main risks of taking bioactive peptides?
Read the original research
Toxicity of Biologically Active Peptides and Future Safety Aspects: An Update.
Current drug discovery technologies, 15(3), 236-242
Citation
Khan, Fazlullah; Niaz, Kamal; Abdollahi, Mohammad. (2018). Toxicity of Biologically Active Peptides and Future Safety Aspects: An Update.. Current drug discovery technologies, 15(3), 236-242. https://doi.org/10.2174/1570163815666180219112806